Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
Auto-generated profile, based on publicly available information
Chuqi Lin
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
Summary: The Chinese government has, in recent decades, implemented various administrative laws and regulatory policies to expedite cancer therapeutic development, boosting research and development pipelines for domestic pharmaceutical companies and clinical trials; however, China faces unique challenges given the high prevalence of certain cancer types and distinct disease burdens, some of which are frequently overlooked by international pharmaceutical companies. Given the substantial unmet need for China-specific cancer care, it is crucial to promote the development of innovative pharmaceutical and clinical research in China, with a particular emphasis on addressing tumors most prevalent in its population.
Supplementary Table 5. The number of clinical trials evaluating Chinese domestic anti-cancer agents regarding different types of cancer from 2018-2023.
Supplementary Table 1. The number of Investigational New Drug (IND) and New Drug Application (NDA) applications retrieved from the Annual Drug Evaluation Report by the Center for Drug Evaluation (CDE) from 2018-2023.
Supplementary Table 4. The incidence rates, in terms of age-standardized rates (ASRs), of the top 20 cancer types in China and globally from the 2022 edition of data of the GLOBOCAN database.